Sound Vaccine, founded in 2016 and based in Seoul, develops and manufactures advanced hearing medical systems and patented hearing‑healthcare products. Its flagship innovations—TSC (Threshold Sound Conditioning) and MDA (Multi‑Dimensional Audiometry)—are covered by numerous patents in the US, Japan, Europe and other regions. The company's core technology includes what it describes as the world’s first non‑invasive hearing improvement method using frequency‑band specific acoustic signals. Its innovations have been clinically proven by Stanford University School of Medicine. Product offerings target both hearing‑loss patients and people with normal hearing who want prevention or enhancement. Sound Vaccine has stated plans to pursue an uplisting on KOSDAQ and says recent financing support will help accelerate its growth and valuation.

Total raised

$141M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2023